Vaccination against the Epstein–Barr virus
| العنوان: | Vaccination against the Epstein–Barr virus |
|---|---|
| المؤلفون: | Carol S. Leung, Christian Münz, Julia Rühl |
| المساهمون: | University of Zurich, Münz, Christian |
| المصدر: | Cellular and Molecular Life Sciences |
| بيانات النشر: | Springer International Publishing, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Epstein-Barr Virus Infections, Herpesvirus 4, Human, Lymphoma, 2804 Cellular and Molecular Neuroscience, Review, medicine.disease_cause, 10263 Institute of Experimental Immunology, 1307 Cell Biology, 0302 clinical medicine, Viral Envelope Proteins, hemic and lymphatic diseases, Cytotoxic T cell, Infectious mononucleosis, 0303 health sciences, biology, Glycoprotein multimers, Vaccination, Virus-like particles, 3. Good health, medicine.anatomical_structure, 3004 Pharmacology, 030220 oncology & carcinogenesis, Molecular Medicine, Antibody, Therapeutic, T cell, 610 Medicine & health, Herpesvirus Vaccines, Neutralizing antibodies, Virus, Prophylactic, Viral vector, 03 medical and health sciences, Cellular and Molecular Neuroscience, Viral envelope, Recombinant viral vectors, Cytotoxic lymphocytes, medicine, 1312 Molecular Biology, Animals, Humans, Vaccines, Virus-Like Particle, Molecular Biology, 030304 developmental biology, Pharmacology, business.industry, Carcinoma, Cell Biology, Virology, Epstein–Barr virus, Antibodies, Neutralizing, 1313 Molecular Medicine, biology.protein, 570 Life sciences, business |
| الوصف: | Epstein–Barr virus (EBV) was the first human tumor virus being discovered and remains to date the only human pathogen that can transform cells in vitro. 55 years of EBV research have now brought us to the brink of an EBV vaccine. For this purpose, recombinant viral vectors and their heterologous prime-boost vaccinations, EBV-derived virus-like particles and viral envelope glycoprotein formulations are explored and are discussed in this review. Even so, cell-mediated immune control by cytotoxic lymphocytes protects healthy virus carriers from EBV-associated malignancies, antibodies might be able to prevent symptomatic primary infection, the most likely EBV-associated pathology against which EBV vaccines will be initially tested. Thus, the variety of EBV vaccines reflects the sophisticated life cycle of this human tumor virus and only vaccination in humans will finally be able to reveal the efficacy of these candidates. Nevertheless, the recently renewed efforts to develop an EBV vaccine and the long history of safe adoptive T cell transfer to treat EBV-associated malignancies suggest that this oncogenic γ-herpesvirus can be targeted by immunotherapies. Such vaccination should ideally implement the very same immune control that protects healthy EBV carriers. |
| وصف الملف: | manuscript_070120.pdf - application/pdf |
| اللغة: | English |
| تدمد: | 1420-9071 1420-682X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348c2d0947cbdc87185ffc287e1ca837Test http://europepmc.org/articles/PMC7223886Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....348c2d0947cbdc87185ffc287e1ca837 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14209071 1420682X |
|---|